Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
BioNTech quietly drops Claudin6 work
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
Allogene ditches enhanced lymphodepletion
The move comes after a death in the Alpha-3 cema-cel study.
Astra’s Neogene investment nosedives
NT-125 is discontinued, while two key Datroway readouts are delayed.
Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Lyell takes on J&J and Gilead
The players are vying in the CD19 x CD20 Car-T arena.
